Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Carparts.Com Inc (PRTS) Price & Performance

Cytokinetics IncTrade
Carparts.Com IncTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Carparts.Com Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.50B), while Carparts.Com Inc trades at $8.59 (market cap $67.00M). The key difference: Cytokinetics Inc is far larger — about 126.9× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Carparts.Com Inc for 45 Days on average.

CYTKPRTS
Market Cap
$8.50B$67.00M
Volume
2,395,55650,584
Sector
HealthConsumer Cyclical
52-Week High
$87.26$10.00
52-Week Low
$54.76$3.88
Typical Hold Time
19 Days45 Days
Enterprise Value
$8.60B$79.96M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.

Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.

Carparts.Com Inc

CarParts.com (PRTS) trades at $8.59, down 0.23% with a bullish technical outlook. The company shows improving quarterly earnings beats but faces fundamental challenges with negative profitability metrics. Recent news highlights the company's focus on leveraging proprietary data as a competitive advantage. Technical indicators show strong moving average support while oscillators remain neutral.

The stock presents a mixed picture with strong analyst support (60% buy ratings) but persistent negative earnings. Investment opportunity lies in continued operational improvements and data-driven strategy execution, while risks include sustained negative cash flow and competitive pressures in the auto parts e-commerce sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CYTK
100% Buy0% Sell
Avg holding period · 19 Days
PRTS
0% Buy100% Sell
Avg holding period · 45 Days

Top news

Latest headlines on both assets

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK →

About Carparts.Com Inc

CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.

Read more on PRTS →